BR112013010190A2 - composições de aripiprazol e métodos para a sua administração transdérmica - Google Patents
composições de aripiprazol e métodos para a sua administração transdérmicaInfo
- Publication number
- BR112013010190A2 BR112013010190A2 BR112013010190A BR112013010190A BR112013010190A2 BR 112013010190 A2 BR112013010190 A2 BR 112013010190A2 BR 112013010190 A BR112013010190 A BR 112013010190A BR 112013010190 A BR112013010190 A BR 112013010190A BR 112013010190 A2 BR112013010190 A2 BR 112013010190A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- transdermal administration
- aripiprazole compositions
- aripiprazole
- compositions
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title 1
- 229960004372 aripiprazole Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Developing Agents For Electrophotography (AREA)
- Secondary Cells (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40759110P | 2010-10-28 | 2010-10-28 | |
PCT/US2011/057080 WO2012058091A2 (en) | 2010-10-28 | 2011-10-20 | Aripiprazole compositions and methods for its transdermal delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013010190A2 true BR112013010190A2 (pt) | 2016-09-13 |
BR112013010190B1 BR112013010190B1 (pt) | 2019-12-31 |
Family
ID=45994667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013010190A BR112013010190B1 (pt) | 2010-10-28 | 2011-10-20 | composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (2) | US9138402B2 (pt) |
EP (1) | EP2632463B1 (pt) |
JP (2) | JP5966228B2 (pt) |
CN (2) | CN107929239B (pt) |
AU (1) | AU2011320758B2 (pt) |
BR (1) | BR112013010190B1 (pt) |
CA (1) | CA2816203C (pt) |
ES (1) | ES2675913T3 (pt) |
MX (1) | MX339196B (pt) |
RU (1) | RU2589689C2 (pt) |
WO (1) | WO2012058091A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
WO2014172344A1 (en) * | 2013-04-16 | 2014-10-23 | Alpha To Omega Pharmaceutical Consultants, Inc. | Pharmaceutical compositions |
US10356018B2 (en) * | 2014-01-31 | 2019-07-16 | Vivint, Inc. | User management methods and systems |
CN107920989A (zh) * | 2015-06-08 | 2018-04-17 | 考里安国际公司 | 用于透皮递送阿立哌唑的制剂 |
WO2017025912A1 (en) * | 2015-08-13 | 2017-02-16 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
JP2019515032A (ja) * | 2016-04-25 | 2019-06-06 | 大塚製薬株式会社 | 摂取型イベントマーカーを有する医薬品の組成物 |
EP3441068A4 (en) * | 2016-05-12 | 2019-04-10 | FUJIFILM Corporation | TRANSDERMALES PREPARATION |
WO2018117125A1 (ja) * | 2016-12-19 | 2018-06-28 | 富士フイルム株式会社 | 経皮製剤 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101492A0 (en) | 1992-04-03 | 1992-12-30 | Shalom Levy | Anti-skin rash preparation |
US5616602A (en) * | 1993-07-09 | 1997-04-01 | Ciba-Geigy Corporation | Topically administrable zinc phthalocyanine compositions |
ATE200979T1 (de) * | 1994-02-18 | 2001-05-15 | Drossapharm Ag | Transdermales therapeutisches system |
US5558071A (en) * | 1994-03-07 | 1996-09-24 | Combustion Electromagnetics, Inc. | Ignition system power converter and controller |
IL134830A0 (en) * | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
DE10030716A1 (de) * | 2000-06-23 | 2002-01-03 | Degussa | Tieftemperaturschlagzähe Polymerlegierung |
DE10110953A1 (de) * | 2001-03-07 | 2002-09-19 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten |
US20040170672A1 (en) * | 2001-03-07 | 2004-09-02 | Thorsten Selzer | Transdermal therapeutic system for administration of partial dopamine-d2 agonists |
CA2428237C (en) | 2003-05-08 | 2010-07-20 | Delmar Chemicals Inc. | Process for the preparation of carbostyril derivatives |
JP4836797B2 (ja) * | 2003-10-23 | 2011-12-14 | 大塚製薬株式会社 | 放出制御性無菌注射アリピプラゾール製剤および方法 |
PT1613598E (pt) | 2003-12-16 | 2012-01-13 | Teva Pharma | Métodos para preparar formas cristalinas de aripiprazol |
CA2622758A1 (en) * | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
KR101329658B1 (ko) * | 2006-09-25 | 2013-11-14 | 아처 다니엘 미드랜드 캄파니 | 초흡수성 표면처리된 카르복시알킬화 다당류 및 그 제조방법 |
CA2665105A1 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and its' process of preparation |
US20130084243A1 (en) * | 2010-01-27 | 2013-04-04 | Liliane Goetsch | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
EP2889029A1 (en) * | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
GB0905365D0 (en) * | 2009-03-27 | 2009-05-13 | Norbrook Lab Ltd | A topical parasiticide composition |
EP2238976B1 (en) * | 2009-04-03 | 2012-06-27 | Hexal AG | Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof |
US8815261B2 (en) * | 2009-06-19 | 2014-08-26 | Medrx Co., Ltd. | Composition for external application comprising aripiprazole and organic acid as active ingredients |
US20110028412A1 (en) * | 2009-08-03 | 2011-02-03 | Cappellos, Inc. | Herbal enhanced analgesic formulations |
US9358261B2 (en) * | 2011-10-25 | 2016-06-07 | U.S. Phytotherapy, Inc. | Additional artemisinin and berberine compositions and methods of making |
US9968740B2 (en) * | 2014-03-25 | 2018-05-15 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
US9468206B2 (en) * | 2014-12-31 | 2016-10-18 | Valent U.S.A., Corporation | Lactofen and dicamba diglycol amine liquid formulations |
-
2011
- 2011-10-20 JP JP2013536677A patent/JP5966228B2/ja active Active
- 2011-10-20 AU AU2011320758A patent/AU2011320758B2/en not_active Ceased
- 2011-10-20 ES ES11836886.9T patent/ES2675913T3/es active Active
- 2011-10-20 CN CN201711272197.4A patent/CN107929239B/zh not_active Expired - Fee Related
- 2011-10-20 WO PCT/US2011/057080 patent/WO2012058091A2/en active Application Filing
- 2011-10-20 RU RU2013124401/15A patent/RU2589689C2/ru active
- 2011-10-20 CA CA2816203A patent/CA2816203C/en active Active
- 2011-10-20 CN CN201180052667.0A patent/CN103491961B/zh not_active Expired - Fee Related
- 2011-10-20 US US13/879,485 patent/US9138402B2/en active Active
- 2011-10-20 BR BR112013010190A patent/BR112013010190B1/pt not_active IP Right Cessation
- 2011-10-20 EP EP11836886.9A patent/EP2632463B1/en active Active
- 2011-10-20 MX MX2013004693A patent/MX339196B/es active IP Right Grant
-
2012
- 2012-11-05 US US13/668,500 patent/US20130171237A1/en not_active Abandoned
-
2016
- 2016-06-16 JP JP2016119741A patent/JP2016164204A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN107929239A (zh) | 2018-04-20 |
US20130171237A1 (en) | 2013-07-04 |
BR112013010190B1 (pt) | 2019-12-31 |
EP2632463A2 (en) | 2013-09-04 |
EP2632463A4 (en) | 2016-04-20 |
AU2011320758A1 (en) | 2013-05-09 |
CN107929239B (zh) | 2021-06-01 |
RU2013124401A (ru) | 2014-12-10 |
MX2013004693A (es) | 2013-11-01 |
JP2016164204A (ja) | 2016-09-08 |
CA2816203C (en) | 2017-02-21 |
JP5966228B2 (ja) | 2016-08-10 |
US9138402B2 (en) | 2015-09-22 |
ES2675913T3 (es) | 2018-07-13 |
JP2014503479A (ja) | 2014-02-13 |
WO2012058091A3 (en) | 2013-10-17 |
CN103491961B (zh) | 2018-01-02 |
RU2589689C2 (ru) | 2016-07-10 |
US20130209552A1 (en) | 2013-08-15 |
CN103491961A (zh) | 2014-01-01 |
AU2011320758B2 (en) | 2015-09-24 |
WO2012058091A2 (en) | 2012-05-03 |
CA2816203A1 (en) | 2012-05-03 |
MX339196B (es) | 2016-05-16 |
EP2632463B1 (en) | 2018-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201700008B (it) | Composizione farmaceutica | |
BR112013010190A2 (pt) | composições de aripiprazol e métodos para a sua administração transdérmica | |
BR112014005744A2 (pt) | composições de peptídeo glucagon-like-2 e métodos para sua produção e utilização | |
ZA201400525B (en) | Rspo binding agents and uses thereof | |
DK3246018T3 (da) | Farmaceutisk sammensætning | |
BR112013019280A2 (pt) | composições wnt e métodos para sua utilização | |
BR112014015042A2 (pt) | composição farmacêutica, e, método para obter uma composição radiofarmacêutica | |
BR112013014644A2 (pt) | composição farmacêutica e complexo | |
EE201300005A (et) | Ravimkoostis | |
BR112013006131A2 (pt) | inibidores de notum pectinacetilesterase e métodos para sua utilização | |
BR112013003276A2 (pt) | dispositivo e método para destacar produtos | |
EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
CO6842019A2 (es) | Formulación liofilizada que contiene aripiprazol | |
SMT201500005B (it) | Composizione framaceutica inalabile | |
CO6781494A2 (es) | Composición lubricante y método para su preparación | |
EP2685993A4 (en) | PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF | |
BR112015002646A2 (pt) | composto e composição farmacêutica | |
BR112012029461A2 (pt) | composição farmacêutica contendo solifenacina | |
BR112013013415A2 (pt) | composição farmacêutica, e, método para a preparação de uma composição | |
BR112014001959A2 (pt) | derivado de camptotencina solúvel em água, composição farmacêutica e aplicação dos mesmos | |
BR112013029331A2 (pt) | composições e métodos para a alteração dos fenótipos xlhed | |
BR112014016122A8 (pt) | composto, e, composição farmacêutica | |
FI20116069L (fi) | Rullatyönnin ja rullan pultti rullatyönnintä varten | |
CO6990712A2 (es) | Combinación farmacéutica antineuritica y composiciones | |
BR112013013309A2 (pt) | processos para a preparação de enaminas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: AEQUUS PHAMACEUTICALS INC. (CA) |
|
B25A | Requested transfer of rights approved |
Owner name: AEQUUS PHAMACEUTICALS INC. (CA) |
|
B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: AEQUUS PHARMACEUTICALS INC. (CA) |
|
B25E | Requested change of name of applicant rejected |
Owner name: AEQUUS PHARMACEUTICALS INC. (CA) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/10/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25A | Requested transfer of rights approved |
Owner name: ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC. (US) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: AEQUUS PHARMACEUTICALS INC. (CA) Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2633 DE 22/06/2021 POR TER SIDO INDEVIDA. |
|
B25A | Requested transfer of rights approved |
Owner name: ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC. (US) |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2693 DE 16-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |